The Washington Times

Alzheimer’s drug fails in 1 study, 2nd continues

continued from page 1

Pfizer said in a statement that the test results from what’s called Study 302 have been shared with government regulators and doctors conducting the study so that patients participating in all the studies can be notified.

“While we are disappointed in the topline results of Study 302, a more complete understanding of bapineuzumab and its potential utility in mild-to-moderate Alzheimer’s disease will be gained following the availability of additional data,” Dr. Steven J. Romano, Pfizer’s head of primary care medicines development, said in a statement.

Bapineuzumab is an antibody-based drug that targets the beta-amyloid protein, the sticky plaque that clogs patients’ brains and is believed to play a central role in development of Alzheimer’s disease. Researchers are still analyzing the study’s data on biomarkers _ spinal fluid and brain imaging _ to see if bapineuzumab had any effect on clearing amyloid. If so, that might lend support to trying the drug earlier in the course of the disease, before people have so much plaque that it causes symptoms. The biomarker results will be presented at scientific conferences this fall, Sperling said.

Biomarkers are genes or measurable characteristics that indicate a normal biologic process, a disease or a response to a treatment.

“I would defer complete judgment on the drug until I see some biomarker data,” said Dr. Ronald Petersen, director of the Mayo Clinic’s Alzheimer’s Disease Research Center. “It still may leave the door open for some positive news if there are any biomarker movements.”

Many scientists believe the drugs are being tried too late, “like lowering the cholesterol after the heart attack,” said Petersen.

He had no role in these studies but consults for Pfizer on other potential Alzheimer’s treatments.

___

AP Chief Medical Writer Marilynn Marchione in Milwaukee contributed to this report.

___

Linda A. Johnson can be followed at http://twitter.com/LindaJ_onPharma

Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Comments
blog comments powered by Disqus
You Might Also Like
  • IRS official Lois Lerner is sworn in on Capitol Hill in Washington on May 22, 2013, before the House Oversight Committee hearing to investigate the extra scrutiny IRS gave to tea party and other conservative groups that applied for tax-exempt status. Lerner told the committee she did nothing wrong and then invoked her constitutional right to not answer lawmakers' questions. (Associated Press)

    IRS head Lois Lerner, who invoked 5th Amendment, may be compelled to testify

  • President Obama answers questions during his new conference in the Brady Press Briefing Room of the White House in Washington on April 30, 2013. (Associated Press)

    Obama defends drone strikes, reignites Gitmo debate in crucial speech

  • ** FILE ** Sen. Ted Cruz, R-Texas, accompanied by Rep. Michele Bachmann, R-Minn., chair of the tea party caucus, speaks during a news conference with tea party leaders about the IRS targeting tea party groups, Thursday, May 16, 2013, on Capitol Hill in Washington. (AP Photo/Molly Riley)

    Conservatives propose compromise of balanced budget, higher debt limit

  • Celebrities In The News
  • Backstreet Boys singer-songwriter Nick Carter has written the memoir "Facing the Music and Living to Talk About It." (AP Photo/Bird Street Books)

    Nick Carter: Backstreet Boy pens memoir

  • Debbie Reynolds: We all knew Liberace was gay

  • "Glee" star Lea Michele attends the Fox Network 2013 Upfront party at Wollman Rink in Central Park in New York on Monday, May 13, 2013. (Evan Agostini/Invision/AP)

    Lea Michele: ‘Glee’ star has book scheduled for 2014